Clinical analysis of EGFR-TKI sequential chemotherapy in the treatment of EGFR-TKI-acquired advanced non-small cell lung cancer
Objective To study the clinical efficacy of EGFR-TKI sequential chemotherapy in the treatment of EGFR-TKI-acquired advanced non-small cell lung cancer (NSCLC). Methods 80 patients with EGFR-TKI acquired advanced NSCLC were divided into two groups. The control group was received chemotherapy alone; and the observation group was treated with EGFR-TKI sequential chemotherapy. The quality of life and the occurrence of adverse reactions were compared between the two groups. Results The clinical effect of the observation group was significantly higher than the control group (P<0.05); the cases in two groups had nausea, vomiting, alopecia, leukopenia and rash, there was a significant difference between the two groups in the incidence of leukopenia and rash (P<0.05). Conclusion EGFR-TKI sequential chemotherapy is effective in the treatment of EGFR-TKI-resistant advanced NSCLC with safety and could improve the quality of life of patients.
NETL
NSTL
万方数据
维普
